Management of HCV-infected patients after successful direct-acting antiviral therapy

Le résumé fourni par la source

Direct-acting antivirals (DAAs) have revolutionized the treatment of chronic hepatitis C virus (HCV) infection, achieving sustained virological response (SVR) in over 95% of patients.This breakthrough has transformed HCV infection from a progressive chronic disease into one that is curable, significantly reducing liver-related complications and mortality.However, viral eradication does not always mean the end of clinical follow-up.Patients with advanced liver disease, comorbidities, or ongoing risk behaviors may remain at risk for disease progression, longterm complications, or reinfection.With the increasing number of individuals achieving SVR, clinicians face the challenge of defining optimal post-cure management strategies, including the frequency and type of monitoring, risk stratification, and preventive measures.This review summarizes current evidence and guideline recommendations for post-SVR care, emphasizing individualized approaches based on baseline liver disease severity, patient comorbidities, and continued exposure to risk factors.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.